Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Therapeutic Use of LSD in Psychiatry, A Systematic Review of Randomized-Controlled Clinical Trials

  • Fuentes, Juan José
  • Fonseca, Francina|||0000-0002-0779-6545
  • Elices, M.|||0000-0002-7034-4242
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Torrens, Marta
Lysergic acid diethylamide (LSD) was studied from the 1950s to the 1970s to evaluate behavioral and personality changes, as well as remission of psychiatric symptoms in various disorders. LSD was used in the treatment of anxiety, depression, psychosomatic diseases and addiction. However, most of the studies were not performed under contemporary standards, and it has taken several decades for a resurgence of interest in LSD research and its therapeutic potential for psychiatry. The aim of this review is to identify controlled and randomized clinical trials that assess the potential use of LSD in psychiatry. PRISMA guidelines for systematic review were followed. A literature search of PubMed and Psychedelic bibliography from Multidisciplinary Association for Psychedelic Studies (MAPS) databases was performed as well as a manual search of references from evaluated studies. Only randomized-controlled clinical trials were included. Study quality was systematically calculated by using the Cochrane Collaboration Tool for assessing risk of bias. A final selection of 11 articles was made after considering inclusion and exclusion criteria. LSD was administered to 567 patients in a dose ranging from 20 to 800 mcg. Despite the design heterogeneity of clinical trials, positive results were observed, thus revealing the therapeutic potential of LSD to reduce psychiatric symptomatology, mainly in alcoholism. The vast majority of authors describe significant and positive short-term changes in patients, despite the fact that in some studies an important homogenization was observed between the LSD treatment group and control group at long-term follow-up. Multiple variables regarding LSD treatment therapeutic approach and quality of experience were revealed and related to therapeutic outcomes. LSD is revealed as a potential therapeutic agent in psychiatry; the evidence to date is strongest for the use of LSD in the treatment of alcoholism. Despite the difficulty of designing proper double blind clinical trials with this substance, new studies that conform to modern standards are necessary in order to strengthen our knowledge on its use and open new doors in the future.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Transitioning From Preclinical Evidence to Advanced Therapy Medicinal Product, A Spanish Experience

  • Gastelurrutia, Paloma|||0000-0001-6974-9210
  • Prat-Vidal, Cristina|||0000-0002-5621-1101
  • Vives Armengol, Joaquim|||0000-0001-9719-5235
  • Coll-Bonet, Ruth|||0000-0003-0174-379X
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Gálvez-Montón, Carolina|||0000-0003-2254-9371
A systematic and ordered product development program, in compliance with current quality and regulatory standards, increases the likelihood of yielding a successful advanced therapy medicinal product (ATMP) for clinical use as safe and effective therapy. As this is a novel field, little accurate information is available regarding the steps to be followed, and the information to be produced to support the development and use of an ATMP. Notably, successful clinical translation can be somewhat cumbersome for academic researchers. In this article, we have provided a summary of the available information, supported by our experience in Spain throughout the development of an ATMP for myocardial infarction, from the pre-clinical stage to phase I clinical trial approval.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Absence of antibodies against KIR4.1 in multiple sclerosis, A three-technique approach and systematic review

  • Navas Madroñal, Miquel|||0000-0003-2984-1471
  • Valero-Mut, Ana
  • Martinez-Zapata, Mª José|||0000-0002-5836-1138
  • Simón Talero, Manuel J.
  • Figueroa, Sebastián
  • Vidal-Fernández, Núria|||0009-0008-3749-6448
  • López-Góngora, Mariana
  • Escartín Siquier, Antonio E.
  • Querol, Luis|||0000-0002-4289-8264
Antibodies targeting the inward-rectifying potassium channel KIR4.1 have been associated with multiple sclerosis (MS) but studies using diverse techniques have failed to replicate this association. The detection of these antibodies is challenging; KIR4.1 glycosylation patterns and the use of diverse technical approaches may account for the disparity of results. We aimed to replicate the association using three different approaches to overcome the technical limitations of a single technique. We also performed a systematic review to examine the association of anti-KIR4.1 antibodies with MS. Serum samples from patients with MS (n = 108) and controls (n = 77) were tested for the presence of anti-KIR4.1 antibodies using three methods: 1) by ELISA with the low-glycosylated fraction of recombinant KIR4.1 purified from transfected HEK293 cells according to original protocols; 2) by immunocytochemistry using KIR4.1-transfected HEK293 cells; and 3) by immunocytochemistry using the KIR4.1.-transfected MO3.13 oligodendrocyte cell line. We developed a systematic review and meta-analysis of the association of anti-KIR4.1 antibodies with MS according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We did not detect anti-KIR4.1 antibodies in the MS patients or in controls using ELISA. Neither did we detect any significant reactivity against the antigen on the cell surface using the KIR4.1-transfected HEK293 cells or the KIR4.1-transfected MO3.13 cells. We included 13 prospective controlled studies in the systematic review. Only three studies showed a positive association between anti-KIR4.1 and MS. Clinical and statistical heterogeneity between studies precluded meta-analysis of their results. We found no association between anti-KIR4.1 antibody positivity and MS. Although this lack of replication may be due to technical limitations, evidence from our study and others is mounting against the role of KIR4.1 as a relevant MS autoantigen.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias, An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry

  • Lewczuk, Piotr|||0000-0002-8101-6535
  • Riederer, Peter
  • O'Bryant, Sid E.
  • Verbeek, Marcel M.
  • Dubois, Bruno
  • Visser, Pieter Jelle|||0000-0001-8008-9727
  • Jellinger, Kurt A.
  • Engelborghs, Sebastiaan|||0000-0003-0304-9785
  • Ramirez, Alfredo|||0000-0003-4991-763X
  • Parnetti, Lucilla|||0000-0001-5722-3967
  • Jack Jr, Clifford R.|||0000-0001-7916-622X
  • Teunissen, Charlotte E.|||0000-0002-4061-0837
  • Hampel, Harald
  • Lleó, Alberto|||0000-0002-2568-5478
  • Jessen, Frank
  • Glodzik, Lidia
  • de Leon, Mony J.
  • Fagan, Anne M.
  • Molinuevo, José Luis|||0000-0003-0485-6001
  • Jansen, Willemijn J.
  • Winblad, Bengt|||0000-0002-0011-1179
  • Shaw, Leslie M.
  • Andreasson, Ulf
  • Otto, Markus
  • Mollenhauer, Brit|||0000-0001-8437-3645
  • Wiltfang, Jens
  • Turner, Martin R.
  • Zerr, Inga
  • Handels, Ron
  • Thompson, Alexander G.|||0000-0003-1063-3277
  • Johansson, Gunilla
  • Ermann, Natalia
  • Trojanowski, John Q.|||0000-0002-9239-8794
  • Karaca, Ilker
  • Wagner, Holger
  • Oeckl, Patrick
  • van Waalwijk van Doorn, Linda
  • Bjerke, Maria
  • Kapogiannis, Dimitrios
  • Kuiperij, H.Bea
  • Farotti, Lucia
  • Li, Yi
  • Gordon, Brian A.
  • Epelbaum, Stéphane
  • Vos, Stephanie J.B.|||0000-0002-2045-9818
  • Klijn, Catharina J.M.
  • Van Nostrand, William E.
  • Minguillon, Carolina
  • Schmitz, Matthias
  • Gallo, Carla|||0000-0001-8348-0473
  • Lopez Mato, Andrea
  • Thibaut, Florence|||0000-0002-0204-5435
  • Lista, Simone
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Blennow, Kaj|||0000-0002-1890-4193
  • Kornhuber, Johannes|||0000-0002-8096-3987
In the 12 years since the publication of the first Consensus Paper of the WFSBP on biomarkers of neurodegenerative dementias, enormous advancement has taken place in the field, and the Task Force takes now the opportunity to extend and update the original paper. New concepts of Alzheimer's disease (AD) and the conceptual interactions between AD and dementia due to AD were developed, resulting in two sets for diagnostic/research criteria. Procedures for pre-analytical sample handling, biobanking, analyses and post-analytical interpretation of the results were intensively studied and optimised. A global quality control project was introduced to evaluate and monitor the inter-centre variability in measurements with the goal of harmonisation of results. Contexts of use and how to approach candidate biomarkers in biological specimens other than cerebrospinal fluid (CSF), e.g. blood, were precisely defined. Important development was achieved in neuroimaging techniques, including studies comparing amyloid-β positron emission tomography results to fluid-based modalities. Similarly, development in research laboratory technologies, such as ultra-sensitive methods, raises our hopes to further improve analytical and diagnostic accuracy of classic and novel candidate biomarkers. Synergistically, advancement in clinical trials of anti-dementia therapies energises and motivates the efforts to find and optimise the most reliable early diagnostic modalities. Finally, the first studies were published addressing the potential of cost-effectiveness of the biomarkers-based diagnosis of neurodegenerative disorders.